Protests Might Slow Trials Aimed at Determining if Antiretroviral Drug Viread Could Prevent HIV Infection
June 14, 2005
Protests from AIDS advocates over international trials aimed at determining if Gilead's antiretroviral drug Viread is effective at preventing HIV infection could delay what CDC says is "one of the most important new prevention approaches being investigated today," the San Jose Mercury News reports (Johnson, San Jose Mercury News, 6/13). CDC granted $3.5 million to fund trials in San Francisco and Atlanta to test FDA-approved Viread, which is known generically as tenofovir and has been shown to boost immune response and lower viral levels in the bloodstreams of patients who are resistant to other antiretrovirals. The trials are designed to determine if Viread is safe to use for HIV prevention among men who have sex with men and if using the drug would result in an increase in unsafe-sex practices and higher HIV incidence. If any of the participants contract HIV while taking Viread, researchers can determine whether the strain they contracted is resistant to the drug. In each city, researchers plan to enroll 200 MSM in the double-blind study, in which participants will be assigned to take Viread or a placebo every day for two years (Kaiser Daily HIV/AIDS Report, 3/18). Public health officials in San Francisco began recruiting MSM for the trial in February. The trials are an "exciting prospect," Albert Liu of the San Francisco Department of Public Health, who is overseer of the trials, said, adding, "Because tenofovir is an approved drug, it's something we could get more quickly into the field" (San Jose Mercury News, 6/13).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.